2020: Beneli AB was acquired by Volati Tryck Holding AB

When we sum up 2020, we are happy and proud of the trust placed in us to represent the seller side in the captioned transaction.

Beneli AB in Helsingborg was founded in 1991. The company develops, manufactures and sells self-adhesive labels for both groceries and industrial products. The company also has a unique position with regards to medical technology labels that are attached to the skin for monitoring and diagnosis within the healthcare sector. The 2019 revenue was SEK 156 million and the company has approximately 60 employees.

Volati is a Swedish industrial group founded in 2003. The group has operations in 16 countries, over 2,000 employees and an annual turnover of approximately SEK 7 billion. The acquisition was a supplementary acquisition to the Industry business area and the Ettiketto business unit.

Beneli’s owners were advised by HWF Advokater in the transaction and Livingstone acted as financial advisor.

Ortoma AB (publ) makes a directed share issue

Ortoma AB (publ) makes a directed share issue of a total of 1 801 898 B-shares. Through the directed issue approximately 39,6 MSEK is invested in Ortoma before transaction related costs. The subscribers are a group of professional investors. 

Ortoma was advised by HWF Advokater in connection with the directed share issue.


CWS Group, a complete service provider in the solution areas Hygiene, Workwear and Fire Safety, announced the acquisition of 100% of the shares of Clean Step AB. Clean Step is a supplier of dust control mats and related services.

HWF Advokater advised the sellers in the transaction.

Tilgmann Group divests Scandiflex Pac AB

Tilgmann Group has reorganized its operations and divested Scandiflex Pac AB to Schur Flexibles. Scandiflex, founded in 1985, is a designer and manufacturer of packaging solutions, predominantly for the food industry but also within other product areas. The company has its headquarters in Landskrona, Sweden, and its turnover during 2018 amounted to approximately SEK 175 million.

Tilgmann Group, founded almost 150 years ago, is active within the packaging business in the Nordic countries.

Tilgmann was advised by HWF Advokater in the transaction.

Diaprost AB announces exercise of option right under the terms of a Research and Option Agreement

In October 2017 Diaprost AB entered into an exclusive Research and Option Agreement with a world leading pharmaceutical company regarding Diaprost’s antibody h11B6. The antibody which targets prostate cancer, the most common cancer in men, has now advanced to clinical development. Taking this into account, the pharmaceutical company has chosen to exercise its option right pursuant to the Research and Option Agreement acquiring Diaprost’s rights to the antibody h11B6. Diaprost has already received payments of USD 13 million and the option and other commercial milestones may trigger additional payments to Diaprost up to USD 90 million.

Diaprost is a private pharmaceutical research and development company which was founded in 2005. The company is based in Lund. Diaprost’s technology has been pursued by researchers at Lund University with support from private investors. Diaprost is collaborating with leading international experts in the fields of molecular medicine, biotechnology, immunology, radiology, radiation physics, laboratory medicine and oncology.

HWF Advokater has jointly with attorney-at-law Ragnar Lindqvist assisted Diaprost in connection with the Research and Option Agreement entered into with the pharmaceutical company and the exercise of the latter’s option right.

EQL Pharma is preparing a listing on Nasdaq Stockholm

The Board of Directors of EQL Pharma AB (publ) has resolved to evaluate the conditions for listing the company’s share on Nasdaq Stockholm’s main list. The list change is expected to take place during the last quarter of 2020. EQL Pharma’s Board of Directors and management will now initiate the work required to prepare the company for a listing on Nasdaq Stockholm.

EQL Pharma’s share has been listed on Spotlight Stock Market since 2013 and in Spotlight’s new segment Next since October 31, 2019. Companies traded in this segment follow stricter rules regarding, among other things, accounting principles than other companies listed on Spotlight Stock Market. The requirements correspond in several respects to the requirements on Nasdaq Stockholm’s main list.

EQL Pharma has engaged HWF Advokater as legal advisor for the planned list change.


Signatur Fastigheter AB (publ) (previously Deflamo AB (publ)), listed on Nasdaq First North Growth Market, and the owners of SIG Invest AB (publ) entered an agreement during the autumn regarding Signatur Fastigheter’s acquisition of all shares in SIG Invest through an issue in kind. The transaction entailed that Deflamo’s business would be changed to SIG Invest’s business whose business idea is to create long-term growth and to increase value through development of residential properties combined with management. After Nasdaq’s conditional approval was obtained, an extraordinary general meeting held on 22 November 2019 resolved to complete the reverse acquisition. In connection with the transaction, Deflamo changed company name to Signatur Fastigheter AB (publ). First trading day on Nasdaq First North Growth Market for the new shares in Signatur Fastigheter was 17 December 2019.

Signatur Fastigheter was advised by HWF Advokater in the reverse acquisition.